You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 17, 2024

LODOCO Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Lodoco, and what generic alternatives are available?

Lodoco is a drug marketed by Agepha Pharma Fz and is included in one NDA. There are ten patents protecting this drug.

This drug has eighty patent family members in twenty-five countries.

The generic ingredient in LODOCO is colchicine. There are sixteen drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the colchicine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Lodoco

A generic version of LODOCO was approved as colchicine by AMNEAL PHARMS on September 28th, 2016.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for LODOCO?
  • What are the global sales for LODOCO?
  • What is Average Wholesale Price for LODOCO?
Summary for LODOCO
International Patents:80
US Patents:10
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Clinical Trials: 2
Drug Prices: Drug price information for LODOCO
What excipients (inactive ingredients) are in LODOCO?LODOCO excipients list
DailyMed Link:LODOCO at DailyMed
Drug patent expirations by year for LODOCO
Drug Prices for LODOCO

See drug prices for LODOCO

Recent Clinical Trials for LODOCO

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of Texas Southwestern Medical CenterPhase 2
Canadian Institutes of Health Research (CIHR)Phase 3
Ottawa Heart Institute Research CorporationPhase 3

See all LODOCO clinical trials

Pharmacology for LODOCO
Drug ClassAlkaloid

US Patents and Regulatory Information for LODOCO

LODOCO is protected by eleven US patents.

Patents protecting LODOCO


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD OF TREATING CARDIOVASCULAR DISEASE


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD OF TREATING AND/OR REDUCING THE RISK OF A CARDIOVASCULAR EVENT; ACUTE CORONARY SYNDROME, OUT-OF-HOSPITAL CARDIAC ARREST, AND/OR NONCARDIOEMBOLIC ISCHEMIC STROKE


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD FOR TREATING AND/OR REDUCING THE RISK OF A CARDIOVASCULAR EVENT


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD OF TREATING AND/OR REDUCING THE RISK OF INFLAMMATION, ATHEROSCLEROTIC VASCULAR DISEASE, AND CHOLESTEROL CRYSTAL INDUCED INFLAMMATION WITHIN ATHEROSCLEROTIC PLAQUES


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD FOR TREATING AND/OR REDUCING THE RISK OF A CARDIOVASCULAR EVENT


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD FOR TREATING AND/OR REDUCING THE RISK OF A CARDIOVASCULAR EVENT


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD FOR TREATING AND/OR REDUCING THE RISK OF ACUTE MYOCARDIAL INFARCTION


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD FOR REDUCING A RISK OF AT LEAST ONE CARDIOVASCULAR EVENT


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD FOR REDUCING A COMPOSITE ENDPOINT RISK OF MYOCARDIAL INFARCTION (MI), STROKE, CORONARY REVASCULARIZATION, UNSTABLE ANGINA REQUIRING HOSPITALIZATION, CARDIAC ARREST, AND CARDIOVASCULAR DEATH


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD FOR REDUCING ACUTE MYOCARDIAL INFARCTION RISK


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING AND/OR REDUCING THE RISK OF A CARDIOVASCULAR EVENT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Agepha Pharma Fz LODOCO colchicine TABLET;ORAL 215727-001 Jun 16, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Agepha Pharma Fz LODOCO colchicine TABLET;ORAL 215727-001 Jun 16, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Agepha Pharma Fz LODOCO colchicine TABLET;ORAL 215727-001 Jun 16, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Agepha Pharma Fz LODOCO colchicine TABLET;ORAL 215727-001 Jun 16, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Agepha Pharma Fz LODOCO colchicine TABLET;ORAL 215727-001 Jun 16, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for LODOCO

See the table below for patents covering LODOCO around the world.

Country Patent Number Title Estimated Expiration
Slovenia 2914255 ⤷  Sign Up
Spain 2870718 ⤷  Sign Up
Japan 2016521270 コルヒチンの徐放性製剤およびその使用方法 ⤷  Sign Up
South Korea 20210020170 콜히친 유도체의 투여를 통한 심혈관성 병태의 치료 또는 예방 (TREATMENT OR PREVENTION OF CARDIOVASCULAR EVENTS VIA THE ADMINISTRATION OF A COLCHICINE DERIVATIVE) ⤷  Sign Up
Slovenia 2986280 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.